Depressive symptoms may influence neuropsychological functioning negatively. A substantial
proportion of multiple sclerosis (MS) patients exhibit neuropsychological impairments and …

Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound
effect on disease activity. The current treatment guidelines only recommend high efficacy …

The discrepancy between chronological age and the apparent age of the brain based on
neuroimaging data — the brain age delta — has emerged as a reliable marker of brain health. …

Introduction The effect of disease-modifying therapies (DMT) on vaccine responses is
largely unknown. Understanding the development of protective immunity is of paramount …

Background: Time matters in multiple sclerosis (MS). Irreversible neural damage and cell
loss occur from disease onset. The MS community has endorsed a management strategy of …

Objective The prevalence of multiple sclerosis (MS)-related fatigue may have changed due
to new diagnostic criteria and new disease modifying drugs. We aimed to assess the …

Immunological hallmarks of multiple sclerosis include the production of antibodies in the
central nervous system, expressed as presence of oligoclonal bands and/or an increased …

Background Diagnostic criteria for multiple sclerosis have been developed to guide the
diagnostic process. In the latest revision of the McDonald criteria, the presence of oligoclonal …

Background Several environmental exposures, including infection with Epstein-Barr virus,
low levels of vitamin D and smoking are established risk factors for multiple sclerosis (MS). …

Background: Many genetic risk variants are now well established in multiple sclerosis (MS),
but the impact on clinical phenotypes is unclear. Objective: To investigate the impact of …